Peer review reports
From: PAFAH1B3 predicts poor prognosis and promotes progression in lung adenocarcinoma
| Original Submission | ||
|---|---|---|
| 13 Apr 2021 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| 4 Aug 2021 | Reviewed | Reviewer Report |
| 27 Sep 2021 | Reviewed | Reviewer Report |
| 30 Dec 2021 | Author responded | Author comments - Zhiyuan Tang |
| Resubmission - Version 4 | ||
| 30 Dec 2021 | Submitted | Manuscript version 4 |
| 20 Jan 2022 | Author responded | Author comments - Zhiyuan Tang |
| Resubmission - Version 5 | ||
| 20 Jan 2022 | Submitted | Manuscript version 5 |
| 8 Feb 2022 | Author responded | Author comments - Zhiyuan Tang |
| Resubmission - Version 6 | ||
| 8 Feb 2022 | Submitted | Manuscript version 6 |
| 28 Feb 2022 | Reviewed | Reviewer Report |
| 9 Mar 2022 | Reviewed | Reviewer Report |
| 18 Apr 2022 | Author responded | Author comments - Zhiyuan Tang |
| Resubmission - Version 7 | ||
| 18 Apr 2022 | Submitted | Manuscript version 7 |
| 26 Apr 2022 | Author responded | Author comments - Zhiyuan Tang |
| Resubmission - Version 8 | ||
| 26 Apr 2022 | Submitted | Manuscript version 8 |
| Publishing | ||
| 27 Apr 2022 | Editorially accepted | |
| 9 May 2022 | Article published | 10.1186/s12885-022-09617-x |